{"name":"Aurinia Pharmaceuticals","slug":"aurinia","ticker":"AUPH","exchange":"NASDAQ","domain":"auriniapharma.com","description":"Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.","hq":"Victoria, British Columbia, Canada","founded":0,"employees":"128","ceo":"Peter Bhatt","sector":"Autoimmune / Nephrology","stockPrice":15.98,"stockChange":-0.05,"stockChangePercent":-0.31,"marketCap":"$2.1B","metrics":{"revenue":298295008,"revenueGrowth":24.4,"grossMargin":78.3,"rdSpend":32505000,"netIncome":287202000,"cash":378524000,"dividendYield":0,"peRatio":7.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"LUPKYNIS patent cliff ($1.4B at risk)","drug":"LUPKYNIS","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LUPKYNIS","genericName":"LUPKYNIS","slug":"lupkynis","indication":"Lupus nephritis (Class III or IV)","status":"marketed"}]}],"pipeline":[{"name":"LUPKYNIS","genericName":"LUPKYNIS","slug":"lupkynis","phase":"marketed","mechanism":"LUPKYNIS (voclosporin) is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce lupus nephritis inflammation.","indications":["Lupus nephritis (Class III or IV)"],"catalyst":""}],"recentEvents":[{"date":"2023-02-22","type":"earnings","headline":"Aurinia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Aurinia Pharmaceuticals reported its financial results for the fourth quarter and full year 2022, with revenue of $143.4 million and a net loss of $44.6 million.","drugName":"","sentiment":"neutral"},{"date":"2022-06-01","type":"regulatory","headline":"Aurinia Pharmaceuticals Announces FDA Approval of LUPKYNIS for the Treatment of Active Lupus Nephritis","summary":"Aurinia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNIS (voclosporin) for the treatment of adult patients with active lupus nephritis.","drugName":"LUPKYNIS","sentiment":"positive"},{"date":"2022-05-16","type":"deal","headline":"Aurinia Pharmaceuticals Announces Collaboration with the Lupus Research Alliance","summary":"Aurinia Pharmaceuticals announced a collaboration with the Lupus Research Alliance to support research and education initiatives for lupus nephritis.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPdDgzQU1MbHZwQTA5dmhzSDY3SGhvWFVfd2I0NnBTRHNNTDJ3Wm1aZGo0T3ZfUnlzV1Y0TnVjQ2txNUppdVU3TU5VQ01ycC1Jc3RSRjVKNmIxeDVSaWR3T2VGSUNOQUtRbjVQTUNRN1I0OS1VRUJTTmNtZjFkTUFDa0F2U0tmMmFBVXBrY1AxcWF2UDhvSzlDbXprOGE?oc=5","date":"2026-03-23","type":"pipeline","source":"Business Wire","summary":"Aurinia Announces Management Transition - Business Wire","headline":"Aurinia Announces Management Transition","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQdmlya3JJeHF0TE1oT29lcDVZZzlndC0wZ19hU3NLVGtQWndqd0NzQmsxSUlUQlU3MGZiWDE0Rmx5WFNJYlRVMjI0UC1VSklURFlvVjBTRDRkVXB6ZFBIWm1JTUlXb3hJckV2bDFVOVcwMEpTbG14OUVPc2FCRjA0eG0zZ1k3OGs3Tm9BVnpxWjRUdHhMV0tBeU9nY1pyTVE4SllHSGhCMUs2N1BPelVFQUl6Zk01WkVybGdDS1B3RmFwcUZmQVhybTFVUUR1NFU?oc=5","date":"2026-02-26","type":"earnings","source":"Stocktwits","summary":"AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates - Stocktwits","headline":"AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates","sentiment":"negative"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxOenc2MHNIS1FraHJVeTZySzFEbXJNR2d5NnFjeVpwQTQwSEtEVUdKc3Fqd0g2aHBBSkg1czNzc19vdnJNSDhiemhncjhYUHQxY05EeE9qYWx3SEtNa3hCUHF4LUszV0ZKa3dkMXp4ckNiSUQwNTliWVVIRkJmWnB0WU9VUDl0NVc2emJURHVfd1FWelU5ejdyMG14OFQyUmNETk9sNFFCajhsSGg1Tnk1UzlQX1dWUzhHb2xJSldITGNhOHpOOFpLZG1NTWxZbXlIY0hNaHBOeDg1cURWWnNBNkdhSDVWQUQzSVVtdkk1dHNwcVhRdVZYZ2UxV3dwUDZVaGJvNDRGSUs1U3RVNDVhbjFJdS1oR2pJRWhLZU5jd0htYXM1Q0picGppa1hCU1VzWENrUEVJTUdZMFdubjU1cWl2NTJYaWthaF9jY1ozVQ?oc=5","date":"2026-02-19","type":"pipeline","source":"Business Wire","summary":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 - Business Wire","headline":"Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNcGxnc2JvQjNTUGx6VG01MlRZOG5fU2NrejlDRExBM3UzOHAyM0s3VUhpTTBNcGE0WVJVS0Z3NWxXcXFzamc1M1BybjZEUlZLYjBPUlU2WlJEdUhYMXhOTUNLZldaa01uQkdLVkprR29MTkFHc01PeThGR2QzeW40bmY0TTlZMFBaZkd3azRKQW42VWV5Y05id2xyT0RITnJZXzdsUnBYNzJ0c1lSU2N0Yks5SG1CWS1TajQ0cmFjU3hoOFU?oc=5","date":"2026-02-06","type":"earnings","source":"Investor's Business Daily","summary":"This Pharma Stock With Earnings Seen Soaring 1,854% Forms Bullish Base - Investor's Business Daily","headline":"This Pharma Stock With Earnings Seen Soaring 1,854% Forms Bullish Base - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNZ0JFZFBCVElKc0w2LTd2VWJuMXk4YmN2aVU1TDBHUUxIOUNYU0U1ZmJiQUF6TjRoRUZvRm02aVVQaGt5Ti1IOHBtWWtzNUZ1SGlfSGFpbXVzSFVUNmxwMVBTUG1yVGM3QlRKVk9IODZ4eGFCR1pPMjdhMHlmel90XzEtanItSU5rNEJLeU1mQzZrZ25pODN4UnBQTGY1TF9Ha1QyLXdCcFFSbFRBS3h1aGU0QXZKekFvRzc4MU9fVnZUcmFna0Q5a21xNDhyQ3R6X2ZJOHBXSVlxRmY2MlE?oc=5","date":"2025-11-03","type":"regulatory","source":"Stocktwits","summary":"FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ - Stocktwits","headline":"FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulati","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNUUtnMWd3ZlItTWlPSUV3NXFET2x5QzE2NE9WRUJ3R3BwajhBWjRFaWl2bDlqMEcxTGdUZWJnSlZnaWFMZF9tZ3h0cTZSMlZKQlo0Z0VBSkprV2NubFdfMWZ6Z0FOLXFDdDV0elBoVzJzdFc0YWdKOHROczlGYzMxYWlvMy1NOW51alRKZnVUQXJ5RXNlN1N6dkN4cVBZMEFidEJ2MXI0S0FEdXpu?oc=5","date":"2025-11-02","type":"regulatory","source":"Seeking Alpha","summary":"Top FDA official Tidmarsh resigns after comments on kidney drug, HHS probe - Seeking Alpha","headline":"Top FDA official Tidmarsh resigns after comments on kidney drug, HHS probe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOX3ZCbFVseWlDTG1rRTFUZ0pzNFFoXzhUNlJMdV9PWFhyRHRGUHpPTkxqQnVrRFdhTFVHZHpIRms5dzhCZ0ZTUXlfSmZDTURybTlqTjEtQzRBMlVLenVMZk94WVNtanE2ZUFWSkJUMHJ4SGZHZDl0ekxIV2tfc092dVB4MXk5MnplZjEwdU1mdEg2LTNQdU9YTzdNRlRZZ2JaNlliVk9QSQ?oc=5","date":"2025-09-29","type":"regulatory","source":"Sherwood News","summary":"Pharma company Aurinia falls after FDA official uses LinkedIn to call out lupus drug - Sherwood News","headline":"Pharma company Aurinia falls after FDA official uses LinkedIn to call out lupus drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNcUw1Nm9rWGFQX0p2aHVpblhPZzFYTTlCeUdmcVNYUmtEUlRUME5vcVZoSzdjTU5HUlh2XzJCd2Rld1FaTjcyLVY0bk92S2ppRmkxRVFHamVVOXNjYzJpdWlsOWFTN0U5UnpBaUxneF9idlktRzdxazlKNW1hbEZ3aldBUFhSYXAyTHlKZnN0WnZObkUxdmlfUkVNSUYwZFlwRXVOLXp6Tml2YTFEWHc?oc=5","date":"2025-08-06","type":"pipeline","source":"Seeking Alpha","summary":"Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade) (NASDAQ:AUPH) - Seeking Alpha","headline":"Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade) (NASDAQ:AUPH)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQYVdHd0ZxRlVDNThyZVVhbVFRZU1la0EzX3NmY0JSWlU3Ul85LTJ0VWt4ZWtiNWFpMzNTeUFsTEFIOTVGazY1VjR6cTlfQmxka3B5NGk0a3RSNFhZSFFsZTI3cXpQYzFyT25tbmpELS1nUXNoWVAtX21ndndQNjVzd0daczNhTE9kMmdSM2FLSnBRYTRZTks2OW80UWotTWI2Tnh0NU9TLXJWM042OHhuU0NmZ3Y?oc=5","date":"2025-08-05","type":"deal","source":"Investing.com","summary":"Aurinia Pharma director Tang buys $13.59m in shares - Investing.com","headline":"Aurinia Pharma director Tang buys $13.59m in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNTS1LQzZPcjYxZEhKNmtfYlBVTzFRNkdLU1BoUEkxOTZ6YmpqTnctYWFNRk5USE5pMTBXMWllUFM4TC1oSlVSekJKemZPS1paeGNFeEVQcWlOdlVBMUw1ZlEzMmxqeHdNLVJBOHFlMkp4M0QyS3NVVTN3MnBaOXZXMUFld2xuLXVDVHVBemNvcFBBYXJJSE1QMnVPbkozUm93UXpzbmduVXZjeGIyalJDcTRBaEZPbklhQnRpLVJWV2V5QnE5ZnNfWUZ5V1ljcXJhU2N4TG9QOXRrUzlwYlQ3a1REQklzSE5iTWV2TTZMRDZaWE0?oc=5","date":"2025-07-22","type":"earnings","source":"Business Wire","summary":"Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - Business Wire","headline":"Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5BUWJzRUNhVXhKY1EzQXp6NHdyd0FZREl3SHZ2UkIySFRDTm5EbmNEMWVrYV83R2ZYUU92UjdOOVVfR2xBZEdZV2pXUno1ZXZX?oc=5","date":"2024-03-26","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"LUPKYNIS","drugSlug":"voclosporin","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["GlaxoSmithKline","Sanofi","Novartis"],"therapeuticFocus":["Autoimmune Diseases","Nephrology"],"financials":{"source":"sec_edgar+yahoo","revenue":283055000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":283055000,"period":"2025-12-31"},{"value":77114000,"period":"2025-12-31"},{"value":73468000,"period":"2025-09-30"},{"value":70008000,"period":"2025-06-30"},{"value":62465000,"period":"2025-03-31"}],"grossProfit":250390000,"grossProfitHistory":[{"period":"2025-12-31","value":250390000},{"period":"2024-12-31","value":206885000},{"period":"2023-12-31","value":161365000},{"period":"2022-12-31","value":128366000}],"rdSpend":32505000,"rdSpendHistory":[{"period":"2025-12-31","value":32505000},{"period":"2024-12-31","value":20785000},{"period":"2023-12-31","value":49641000},{"period":"2022-12-31","value":44988000}],"sgaSpend":101794000,"operatingIncome":106561000,"operatingIncomeHistory":[{"period":"2025-12-31","value":106561000},{"period":"2024-12-31","value":18419000},{"period":"2023-12-31","value":-91691000},{"period":"2022-12-31","value":-111470000}],"netIncome":287202000,"netIncomeHistory":[{"period":"2025-12-31","value":287202000},{"period":"2024-12-31","value":5752000},{"period":"2023-12-31","value":-78020000},{"period":"2022-12-31","value":-108180000}],"eps":2.07,"epsHistory":[{"period":"2025-12-31","value":2.07},{"period":"2024-12-31","value":0.04},{"period":"2023-12-31","value":-0.54},{"period":"2022-12-31","value":-0.76}],"cash":80213000,"cashHistory":[{"period":"2025-12-31","value":80213000},{"period":"2024-12-31","value":83433000},{"period":"2023-12-31","value":48875000},{"period":"2022-12-31","value":94172000}],"totalAssets":751587000,"totalLiabilities":170256000,"totalDebt":74812000,"equity":581331000,"operatingCashflow":135658000,"operatingCashflowHistory":[{"period":"2025-12-31","value":135658000},{"period":"2024-12-31","value":44388000},{"period":"2023-12-31","value":-33461000},{"period":"2022-12-31","value":-79529000}],"capex":-252000,"capexHistory":[{"period":"2025-12-31","value":-252000},{"period":"2024-12-31","value":-281000},{"period":"2023-12-31","value":-718000},{"period":"2022-12-31","value":-292000}],"freeCashflow":135406000,"dividendsPaid":null,"buybacks":-98156000,"employees":128,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":22029000,"ebit":44937000,"ebitda":49753000,"period":"2026-03-31","revenue":77705000,"epsBasic":0.26,"netIncome":34355000,"rdExpense":7470000,"epsDiluted":0.25,"grossProfit":71200000,"operatingIncome":41422000},{"sga":29255000,"ebit":36737000,"ebitda":41601000,"period":"2025-12-31","revenue":77114000,"epsBasic":1.6,"netIncome":210794000,"rdExpense":10895000,"epsDiluted":1.53,"grossProfit":68315000,"operatingIncome":33239000},{"sga":26182000,"ebit":33061000,"ebitda":37926000,"period":"2025-09-30","revenue":73468000,"epsBasic":0.24,"netIncome":31551000,"rdExpense":8435000,"epsDiluted":0.23,"grossProfit":65291000,"operatingIncome":29745000},{"sga":26018000,"ebit":23273000,"ebitda":28137000,"period":"2025-06-30","revenue":70008000,"epsBasic":0.16,"netIncome":21513000,"rdExpense":7432000,"epsDiluted":0.16,"grossProfit":62893000,"operatingIncome":20197000},{"sga":20339000,"ebit":25416000,"ebitda":30272000,"period":"2025-03-31","revenue":62465000,"epsBasic":0.17,"netIncome":23344000,"rdExpense":5743000,"epsDiluted":0.16,"grossProfit":53891000,"operatingIncome":23380000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":15.98,"previousClose":16.03,"fiftyTwoWeekHigh":16.88,"fiftyTwoWeekLow":7.29,"fiftyTwoWeekRange":"7.285 - 16.88","fiftyDayAverage":15.27,"twoHundredDayAverage":14.06,"beta":1.45,"enterpriseValue":1751600768,"forwardPE":14.3,"priceToBook":3.68,"priceToSales":6.89,"enterpriseToRevenue":5.87,"enterpriseToEbitda":11.39,"pegRatio":0,"ebitda":153712000,"ebitdaMargin":51.5,"freeCashflow":124632496,"operatingCashflow":166918000,"totalDebt":68640000,"debtToEquity":12.1,"currentRatio":5.55,"returnOnAssets":13.7,"returnOnEquity":65,"analystRating":"1.9 - Buy","recommendationKey":"buy","numberOfAnalysts":7,"targetMeanPrice":17,"targetHighPrice":21,"targetLowPrice":15,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":7.4,"institutionHeldPercent":59.1,"sharesOutstanding":128601671,"floatShares":126239258,"sharesShort":8886775,"shortRatio":8.07,"shortPercentOfFloat":6.8,"epsTrailing":2.16,"epsForward":1.12,"revenuePerShare":2.25,"bookValue":4.34,"officers":[{"age":58,"name":"Mr. Kevin C. Tang","title":"Chairman & CEO"},{"age":43,"name":"Mr. Stephen P. Robertson","title":"Chief Legal Officer, Corporate Secretary & Chief Compliance Officer"},{"age":55,"name":"Mr. Peter S. Greenleaf M.B.A.","title":"Consultant"},{"age":62,"name":"Mr. Michael S. Hearne CPA","title":"Chief Financial Officer"},{"age":38,"name":"Mr. Ryan  Cole","title":"Chief Operating Officer"},{"age":49,"name":"Mr. Thomas  Wei","title":"Chief Scientific Officer"},{"age":66,"name":"Mr. Stewart M. Kroll","title":"Chief Development Officer"}],"industry":"Biotechnology","irWebsite":"http://www.isotechnika.com/for_investors/","website":"https://www.auriniapharma.com","phone":"250 744 2487"}}